We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
- Authors
Lara, Primo N, Jr; Douillard, Jean-Yves; Nakagawa, Kazuhiko; von Pawel, Joachim; McKeage, Mark J; Albert, Istvan; Losonczy, György; Reck, Martin; Heo, Dae-Seog; Fan, Xiaolin; Fandi, Abderrahim; Scagliotti, Giorgio
- Abstract
This phase III trial was conducted to test whether the novel vascular disrupting agent ASA404 (vadimezan), when combined with first-line platinum-based chemotherapy, improves survival in patients with advanced non-small-cell lung cancer (NSCLC) versus chemotherapy alone.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Vol 29, Issue 22, p2965
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2011.35.0660